Protagonist Therapeutics Achieves Q1 Profitability Fueled by Major FDA Milestones

Newark, Tuesday, 5 May 2026.
Fueled by a $50 million FDA approval milestone and a $200 million strategic opt-out fee, Protagonist Therapeutics achieved a profitable Q1 in 2026, securing operations through 2028.